In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.
In January 2018, Strongbridge Biopharma acquired the U.S. and Canadian rights to MACRILENTM (macimorelin).
In December 2016, Strongbridge Biopharma acquired the U.S. rights to KEVEYIS® (dichlorphenamide).
These acquisitions are part of our commitment to expand our portfolio and help meet the needs of patients with rare diseases that are underdiagnosed and undertreated.
Recent business and clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development and commercialization.
Acquired MACRILEN (macimorelin) from Aeterna Zentaris for the diagnosis of Adult Growth Hormone Deficiency
Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome
Launched KEVEYIS (dichlorphenamide) for Primary Periodic Paralysis
Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis
Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals
First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome
RECORLEV received EU orphan drug designation
RECORLEV received US orphan drug designation
Pivoted RECORLEV focus from diabetes to Cushing's syndrome
The safety and efficacy of RECORLEV™ (levoketoconazole) and veldoreotide have not been established.
© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MACRILEN™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018